Vion Pharmaceuticals, Inc. (OTC:VION) has received a completed response letter from the US Food and Drug Administration (FDA) regarding its New Drug Application for its Onrigin™ injection submitted in February 2009. The letter indicated that the company’s NDA cannot be approved at the time. Recommendations were presented by the FDA to address the remaining issues.
MicroCap Insider is a web-based financial portal.
Sign Up for our Free Stock Newsletter
MicroCap Insider publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors.
A development state pharmaceutical company, Vion Pharmaceuticals is focused on the development of therapeutics for cancer treatment. Its current drugs include Onrigin and Triapine, small molecule anticancer agents currently in clinical development. For more information regarding the company and its product development programs, visit www.vionpharm.com.
Sign Up for FREE. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website.
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer.
